6 assets in Acute Myeloid Leukemia, T(16;16)(P13.1;Q22)

Therapeutic assets addressing Acute Myeloid Leukemia, T(16;16)(P13.1;Q22), rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cytarabine Acute Myeloid Leukemia, T(16;16)(P13.1;Q22)	M.D. Anderson Cancer Center	P2	CCC (53)
Decitabine Acute Myeloid Leukemia, T(16;16)(P13.1;Q22)	M.D. Anderson Cancer Center	P2	CCC (53)
Fludarabine Acute Myeloid Leukemia, T(16;16)(P13.1;Q22)	M.D. Anderson Cancer Center	P2	CCC (53)
Gemtuzumab Ozogamicin Acute Myeloid Leukemia, T(16;16)(P13.1;Q22)	M.D. Anderson Cancer Center	P2	CCC (53)
Idarubicin Acute Myeloid Leukemia, T(16;16)(P13.1;Q22)	M.D. Anderson Cancer Center	P2	CCC (53)
Filgrastim-Sndz Acute Myeloid Leukemia, T(16;16)(P13.1;Q22)	M.D. Anderson Cancer Center	P2	CC (46)